Methamphetamine toxicity presents as an acute sympathomimetic toxidrome characterized by agitation, delirium, tachycardia, hypertension, hyperthermia, and cardiac symptoms. Severe complications include stroke, myocardial infarction, aortic dissection, cardiac arrhythmias, rhabdomyolysis, seizures, and death. [1-3] Management centers on benzodiazepines as first-line therapy, aggressive cooling for hyperthermia, and symptom-directed supportive care. [4-5]
1. History
- Key HPI questions: Substance used, route (smoked, IV, oral, intranasal), amount, time of last use, co-ingestants (opioids, alcohol, GHB), intentional vs recreational use
- Symptom characterization: Chest pain, palpitations, headache, shortness of breath, agitation, paranoia, hallucinations (visual/auditory/tactile), formication ("meth bugs")
- Timing: Onset typically within minutes (smoked/IV) to 30 minutes (oral); half-life ~5–30 hours, so toxicity can be prolonged [6]
- Triggers/progression: Binge use patterns, sleep deprivation (days without sleep), escalating doses
- Associated symptoms: Bruxism, diaphoresis, tremor, anorexia, insomnia, repetitive behaviors
- Important negatives: Suicidal ideation, trauma/falls, body packing/stuffing, pregnancy
2. Alarm Features
- Core temperature >40°C (104°F) — rapidly life-threatening [5]
- Severe hypertension (SBP >180) or hypertensive emergency with end-organ damage
- Chest pain with ECG changes suggesting ACS or aortic dissection
- Seizures or status epilepticus
- Altered mental status / obtundation (consider intracranial hemorrhage)
- Signs of rhabdomyolysis (rigid muscles, dark urine, oliguria)
- Sudden cardiovascular collapse (takotsubo cardiomyopathy, arrhythmia) [2][5]
- Prolonged physical restraint without sedation — associated with death [2][5]
3. Medications
First-line — Agitation/Hyperadrenergic State
- Benzodiazepines (first-line): Midazolam 5 mg IM/IV, lorazepam 2–4 mg IV, diazepam 5–10 mg IV; repeat as needed [4]
- Antipsychotics (adjunct for psychosis/agitation): Olanzapine 5–10 mg IM, droperidol 2.5–5 mg IM/IV (more rapid sedation than lorazepam in one RCT), aripiprazole (least QTc effect) [1]
- Ketamine 4 mg/kg IM for severe refractory agitation when IV access is not possible [4][7]
- Dexmedetomidine for severe refractory symptoms; clonidine for mild-moderate [4][7]
Hypertensive Emergency
- Short-acting agents: sodium nitroprusside, phentolamine, nicardipine/clevidipine (dihydropyridine CCBs) [4]
- Nitroglycerin if signs of cardiac ischemia [4]
- Avoid long-acting antihypertensives (risk of hemodynamic collapse as drug wears off) [4]
Beta-Blocker Controversy
- The ASAM/AAAP guideline recommends beta-blockers with concomitant alpha-1 antagonism (labetalol, carvedilol) if hyperadrenergic state persists after benzodiazepines [4][7]
- The NEJM Evidence review notes that concerns about "unopposed alpha stimulation" have been "repeatedly debunked" for methamphetamine, though no RCTs exist [1]
- Pure beta-blockers remain controversial, particularly with cocaine co-ingestion [4]
Contraindicated/Cautions
- Avoid pure beta-blockers in cocaine co-ingestion [4]
- Avoid long-acting antihypertensives [4]
- Use caution with antipsychotics that prolong QTc (haloperidol, droperidol) — monitor QTc
- Avoid sustained physical restraint without chemical sedation [2][5]
4. Diet
- NPO if severely altered or at risk for aspiration
- Aggressive IV fluid resuscitation — patients are often dehydrated from prolonged sympathomimetic activity, hyperthermia, and poor oral intake
- Chronic users: poor nutritional status, dental disease; address nutritional deficiencies once stabilized [3]
5. Review of Systems
- Cardiovascular: Chest pain, palpitations, dyspnea, syncope
- Neurologic: Headache (worst of life → hemorrhagic stroke), seizures, focal deficits, vision changes
- Psychiatric: Paranoia, hallucinations, suicidal/homicidal ideation, agitation
- GI: Abdominal pain (intestinal ischemia, body packing), nausea/vomiting
- GU: Dark urine (rhabdomyolysis), decreased urine output
- MSK: Muscle rigidity, pain, cramping
- Skin: Excoriations, injection sites, abscesses, diaphoresis
6. Collateral History and Family History
- Collateral: EMS report (scene findings, paraphernalia, bystander accounts), friends/family regarding substance use pattern, duration of binge, co-ingestants, baseline psychiatric history
- Family history: Cardiac disease (cardiomyopathy, arrhythmias, sudden death), psychiatric illness, substance use disorders
- Social context: Housing status, injection drug use, sexual practices (methamphetamine strongly associated with STIs including HIV), involvement with law enforcement, children in the home [3]
7. Risk Factors
- Route: IV and smoked routes → faster onset, higher peak levels, greater toxicity risk
- Binge use patterns and sleep deprivation
- Polysubstance use: Concurrent opioid use (methamphetamine present in 63% of opioid deaths), alcohol, GHB [8]
- Pre-existing cardiovascular disease: Hypertension, cardiomyopathy, coronary artery disease
- Chronic methamphetamine use → cumulative cardiovascular and neurotoxic damage; most deaths result from long-term exposure rather than acute "overdose" [1]
- Psychiatric comorbidities: Pre-existing psychotic disorders lower threshold for methamphetamine-induced psychosis
8. Differential Diagnosis
- Sympathomimetic toxidrome from other agents: Cocaine, synthetic cathinones ("bath salts"), MDMA, PCP
- Serotonin syndrome: Clonus, hyperreflexia, diarrhea — distinguish from pure sympathomimetic toxidrome
- Anticholinergic toxidrome: Dry skin, urinary retention, absent bowel sounds (vs. diaphoresis in sympathomimetic)
- Thyroid storm: Tachycardia, hyperthermia, agitation — check thyroid history
- Neuroleptic malignant syndrome: Rigidity, hyperthermia, altered mental status — recent antipsychotic use
- Meningitis/encephalitis: Fever, altered mental status — consider LP if diagnostic uncertainty
- Primary psychiatric emergency: Mania, acute psychosis — toxicology screen helps differentiate
- Intracranial hemorrhage: Sudden severe headache, focal deficits, hypertension
- Pheochromocytoma: Paroxysmal hypertension, headache, diaphoresis (rare but mimics)
9. Past Medical History
- Prior methamphetamine use and overdoses
- Known cardiomyopathy or heart failure (methamphetamine-associated cardiomyopathy is increasingly recognized) [1]
- Prior stroke or intracranial hemorrhage
- Seizure history
- Psychiatric diagnoses (schizophrenia, bipolar disorder)
- HIV/hepatitis B/C status
- Prior endocarditis, osteomyelitis, or deep infections (IV users) [3][7]
- Dental disease
10. Physical Exam
Vital Signs
- Tachycardia, hypertension (may be severe), hyperthermia, tachypnea
- Core temperature (rectal preferred) — >40°C is a critical threshold [5]
Focused Exam
- Neuro: Pupil dilation (mydriasis), hyperreflexia, clonus, tremor, seizure activity, focal deficits (stroke)
- Psych: Level of agitation (RASS or sedation-agitation scale), psychosis, orientation
- CV: Murmurs (endocarditis), irregular rhythm, signs of heart failure (JVD, crackles, edema)
- Skin: Diaphoresis (vs. dry in anticholinergic), injection track marks, abscesses, excoriations, skin popping scars
- Abdomen: Tenderness (ischemia, body packing), bowel sounds (present in sympathomimetic, absent in anticholinergic)
- Oral: "Meth mouth" — severe dental caries, xerostomia
11. Lab Studies
- Stat labs: BMP (electrolytes, renal function, glucose), CBC, lactate, troponin, CK (rhabdomyolysis), urinalysis (myoglobinuria)
- Toxicology: Urine drug screen (amphetamines positive 1–4 days after use), serum ethanol, acetaminophen, salicylate levels [9]
- If severe: ABG/VBG (acidosis), coagulation studies (DIC), LFTs, lipase
- Expected abnormalities: Metabolic acidosis, hyperkalemia, elevated CK, elevated troponin, AKI [7]
- Monitoring: Serial troponins if chest pain, serial CK if rhabdomyolysis suspected, serial electrolytes
12. Imaging
- Chest X-ray: Cardiomegaly (cardiomyopathy), pulmonary edema, pneumomediastinum (from smoking)
- CT head without contrast: If altered mental status, focal neurologic deficits, severe headache, or seizure — rule out intracranial hemorrhage (cerebrovascular complications account for ~55% of methamphetamine-related deaths with additional causes listed) [1]
- CT angiography of chest/abdomen: If concern for aortic dissection (tearing chest/back pain, pulse differential)
- Echocardiography: If signs of heart failure, new murmur, or elevated troponin — assess for cardiomyopathy or takotsubo [1][5]
- Imaging is unnecessary in mild intoxication with normal vitals, normal mental status, and no focal complaints after observation
13. Special Tests
- Point-of-care ultrasound (POCUS): Cardiac (EF, pericardial effusion, RV dilation), IVC (volume status), lung (B-lines for pulmonary edema)
- Sedation-Agitation Scale (SAS) or RASS: Quantify agitation severity to guide pharmacotherapy
- Urine drug immunoassay: Note — false positives for amphetamines can occur with bupropion, labetalol, pseudoephedrine, trazodone, selegiline; confirmatory GC-MS if needed
14. ECG
- Obtain on all patients with methamphetamine toxicity presenting with chest pain, palpitations, dyspnea, or hemodynamic instability
- Up to 70% of methamphetamine users have an abnormal ECG [9]
- Common findings: Sinus tachycardia (most common), right axis deviation, LVH, P pulmonale, inferior Q waves, lateral T-wave inversions, prolonged QTc [8]
- Dangerous patterns: ST elevation (STEMI from vasospasm or thrombosis), wide QRS (sodium channel blockade if co-ingestant), VT/VF, new atrial fibrillation, Brugada-like pattern
- QTc monitoring is essential if antipsychotics are administered [1]
15. Assessment
Methamphetamine toxicity exists on a spectrum of severity
- Mild: Tachycardia, mild hypertension, anxiety, mydriasis — may resolve with observation and low-stimulus environment
- Moderate: Significant agitation, hypertension (SBP >160), hyperthermia (38–40°C), psychosis — requires pharmacologic intervention
- Severe/Life-threatening: Temperature >40°C, hypertensive emergency, seizures, rhabdomyolysis, ACS, stroke, cardiac arrest [2][5]
Most deaths are attributed to long-term cumulative cardiovascular damage rather than acute overdose, with fatal cardiac arrhythmia being a leading suspected mechanism. [1] Takotsubo cardiomyopathy can be fatal but often resolves spontaneously with supportive care. [5]
16. Treatment Plan
Initial Stabilization (ABCs)
- Airway management if obtunded; RSI if needed (avoid succinylcholine if hyperkalemia/rhabdomyolysis suspected)
- IV access, continuous cardiac monitoring, pulse oximetry
Agitation — Stepwise Approach
- Verbal de-escalation, low-stimulus environment [4]
- Benzodiazepines (first-line): Midazolam 5–10 mg IM or lorazepam 2–4 mg IV; repeat q5–10 min as needed [4]
- Antipsychotics (adjunct): Droperidol 2.5–5 mg IM/IV or olanzapine 5–10 mg IM [1][4]
- Ketamine 4 mg/kg IM for refractory agitation [7]
- Propofol or dexmedetomidine infusion for ICU-level refractory cases [4]
Hyperthermia (>40°C)
- Aggressive external cooling — evaporative cooling or ice water immersion (fastest method, cooling rate >0.15°C/min associated with improved survival) [5]
- Benzodiazepines to reduce heat-generating psychomotor activity
- Antipyretics (acetaminophen) are ineffective — hyperthermia is from muscular activity, not hypothalamic set-point elevation
Hypertensive Emergency
- Benzodiazepines first; if persistent: nicardipine drip, phentolamine, or sodium nitroprusside [4]
- Nitroglycerin if cardiac ischemia present [4]
- Labetalol is acceptable per ASAM/AAAP if benzodiazepines fail [4][7]
Chest Pain / ACS
- Standard ACS workup; nitroglycerin, aspirin, benzodiazepines
- Avoid pure beta-blockers if cocaine co-ingestion suspected [4]
- Cardiology consultation for STEMI or hemodynamic instability
Seizures
Rhabdomyolysis
- Aggressive IV crystalloid resuscitation targeting UOP 1–3 mL/kg/hr
- Monitor CK, electrolytes (hyperkalemia), renal function serially
Cardiac Arrest
- Standard ACLS with emphasis on treating reversible causes
- Consider VA-ECMO for refractory cardiogenic shock from takotsubo cardiomyopathy [2][5]
17. Disposition
Admit (ICU) if
- Hyperthermia >40°C
- Hypertensive emergency with end-organ damage
- ACS / troponin elevation / hemodynamic instability
- Seizures or status epilepticus
- Rhabdomyolysis with AKI or CK >5,000
- Intracranial hemorrhage
- Refractory agitation requiring continuous sedation
- Cardiac arrhythmias
Observation (6–8 hours) if
- Moderate agitation responding to benzodiazepines
- Mild-moderate hypertension trending down
- Awaiting troponin/CK results
- Psychosis clearing with treatment
Discharge if
- Vital signs normalized and stable for ≥1 hour off medications
- Agitation/psychosis resolved
- Ambulating, tolerating PO, normal mental status
- No evidence of end-organ damage (normal troponin, CK, renal function)
- Safe disposition plan (not suicidal/homicidal, able to care for self)
Consult triggers
- Toxicology: Refractory symptoms, diagnostic uncertainty, body packing
- Cardiology: ACS, new cardiomyopathy, arrhythmias
- Neurosurgery: Intracranial hemorrhage
- Psychiatry: Persistent psychosis (>24–48 hours), suicidality
- Addiction medicine: All patients with methamphetamine use disorder — contingency management and CBT are evidence-based treatments [1][3]
18. Follow Up / Return Precautions
- Follow-up timing: PCP or addiction medicine within 1 week; cardiology if cardiomyopathy identified; psychiatry if persistent psychotic symptoms
- Return immediately for: Chest pain, severe headache, weakness/numbness on one side, seizures, dark urine, inability to urinate, return of severe agitation or psychosis, suicidal thoughts
- Patient counseling:
- Methamphetamine-associated cardiomyopathy and stroke risk increase with cumulative use [1]
- Provide take-home naloxone (high rate of opioid co-use) [1]
- Offer harm reduction resources, needle exchange if IV user
- Screen for HIV, hepatitis B/C, STIs [3]
- Discuss treatment options: contingency management, CBT, and off-label medications (mirtazapine, bupropion, naltrexone) [1][3]
- Expected course: Acute sympathomimetic effects typically resolve within 12–24 hours; psychosis may persist days to weeks in chronic users; withdrawal (dysphoria, hypersomnia, increased appetite) begins within hours and peaks at 72 hours [3]
References
1. Methamphetamine Toxicities and Clinical Management. — Coffin PO, Suen LW. NEJM Evidence. 2023.
2. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
3. Methamphetamine Use Disorder. — Leyde S, Tilhou AS, Tsui JI. The Journal of the American Medical Association. 2025.
4. The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. — Journal of Addiction Medicine. 2024.
5. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
6. The Clinical Toxicology of Metamfetamine. — Schep LJ, Slaughter RJ, Beasley DM. Clinical Toxicology. 2010.
7. Management of Stimulant Use Disorder. — Steven Batki MD, Daniel Ciccarone MD MPH, Scott E. Hadland MD MPH, et al American Academy of Addiction Psychiatry (2023). 2023.
8. Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review. — Paulus MP, Stewart JL. JAMA Psychiatry. 2020.
9. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021.